Trial Profile
Lenalidomide Maintenance in Plasma Cell Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 29 Jun 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.
- 29 Jun 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2024.
- 01 Sep 2022 Planned End Date changed from 1 Aug 2022 to 1 Aug 2023.